{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:09:14Z","timestamp":1788728954123,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Chemical Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019717","name":"AstraZeneca Pharmaceutical Spain","doi-asserted-by":"publisher","award":["ES-2021-2040"],"award-info":[{"award-number":["ES-2021-2040"]}],"id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmorw.2024.100107","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T14:55:55Z","timestamp":1737212155000},"page":"100107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study"],"prefix":"10.1016","volume":"7","author":[{"given":"E.","family":"L\u00f3pez-Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tolosa-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Perell\u00f3-Martorell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-6730","authenticated-orcid":false,"given":"L.","family":"S\u00e1nchez-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-7847","authenticated-orcid":false,"given":"C.","family":"Hinojo-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6988-4519","authenticated-orcid":false,"given":"S.","family":"Servitja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Recalde-Penabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Olier-G\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Garc\u00eda-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2289-4936","authenticated-orcid":false,"given":"L.","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-1346","authenticated-orcid":false,"given":"D.","family":"Alcal\u00e1-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"L\u00f3pez-Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jim\u00e9nez-Cortegana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-3410","authenticated-orcid":false,"given":"M.","family":"Sampayo-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Antonarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"P\u00e9rez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Llombart-Cussac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"22","key":"10.1016\/j.esmorw.2024.100107_bib2","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 17","key":"10.1016\/j.esmorw.2024.100107_bib4","volume":"42","author":"Curigliano","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.esmorw.2024.100107_bib5","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/fon-2024-0015","article-title":"Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer","volume":"20","author":"Guarneri","year":"2024","journal-title":"Future Oncol Lond Engl"},{"key":"10.1016\/j.esmorw.2024.100107_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41523-021-00343-4","article-title":"Evolution of HER2-low expression from primary to recurrent breast cancer","volume":"7","author":"Miglietta","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.esmorw.2024.100107_bib7","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/cancers15051413","article-title":"Discordance of HER2-low between primary tumors and matched distant metastases in breast cancer","volume":"15","author":"Almstedt","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.esmorw.2024.100107_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2021.12.022","article-title":"Evolution of low HER2 expression between early and advanced-stage breast cancer","volume":"163","author":"Tarantino","year":"2022","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.esmorw.2024.100107_bib9","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1038\/s41591-023-02625-9","article-title":"Prospective implementation of AI-assisted screen reading to improve early detection of breast cancer","volume":"29","author":"Ng","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib10","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1038\/s41467-021-26023-2","article-title":"Artificial intelligence system reduces false-positive findings in the interpretation of breast ultrasound exams","volume":"12","author":"Shen","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22514-4","article-title":"Artificial intelligence-based methods for fusion of electronic health records and imaging data","volume":"12","author":"Mohsen","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.esmorw.2024.100107_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.106649","article-title":"Natural language processing in electronic health records in relation to healthcare decision-making: a systematic review","volume":"155","author":"Hossain","year":"2023","journal-title":"Comput Biol Med"},{"issue":"4","key":"10.1016\/j.esmorw.2024.100107_bib13","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jvc2.217","article-title":"The DERMACLEAR study: verification results of a natural language processing system in dermatology","volume":"2","author":"Ortiz de Frutos","year":"2023","journal-title":"JEADV Clin Pract"},{"issue":"13","key":"10.1016\/j.esmorw.2024.100107_bib14","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3390\/cancers14133063","article-title":"Considerations for the use of machine learning extracted real-world data to support evidence generation: a research-centric evaluation framework","volume":"14","author":"Estevez","year":"2022","journal-title":"Cancers"},{"issue":"20","key":"10.1016\/j.esmorw.2024.100107_bib15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmorw.2024.100107_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.esmorw.2024.100107_bib17","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG Oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.esmorw.2024.100107_bib18","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmorw.2024.100107_bib19","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.esmorw.2024.100107_bib20","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.esmorw.2024.100107_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"31","key":"10.1016\/j.esmorw.2024.100107_bib24","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmorw.2024.100107_bib25","first-page":"323","article-title":"A\u00a0framework for false negative detection in NER\/NEL","volume":"13286","author":"Quijada","year":"2022"},{"key":"10.1016\/j.esmorw.2024.100107_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2023.104461","article-title":"An open source corpus and automatic tool for section identification in Spanish health records","volume":"145","author":"de la Iglesia","year":"2023","journal-title":"J\u00a0Biomed Inform"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41416-023-02287-x","article-title":"Anticipating changes in the HER2 status of breast tumours with disease progression\u2014towards better treatment decisions in the new era of HER2-low breast cancers","volume":"129","author":"Bergeron","year":"2023","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmorw.2024.100107_bib28","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1038\/s41379-020-0615-z","article-title":"Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution","volume":"33","author":"Chen","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/annonc\/mds248","article-title":"Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis","volume":"24","author":"Dieci","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100107_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41523-021-00252-6","article-title":"Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort","volume":"7","author":"Grinda","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmorw.2024.100107_bib31","doi-asserted-by":"crossref","first-page":"S1213","DOI":"10.1016\/j.annonc.2024.08.2259","article-title":"Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor\u2013positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)","volume":"35","author":"Salgado","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T20:18:11Z","timestamp":1788725891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820124000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":31,"alternative-id":["S2949820124000857"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100107","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human epidermal growth factor receptor 2 (HER2) expression dynamics between diagnosis and recurrence in patients with breast cancer using artificial intelligence and electronic health records: the RosHER study","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100107"}}